Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Epilepsy affects many, with a third resistant to standard treatments.
• Neuroinflammation and the endocannabinoid system are implicated in epilepsy.
• Cannabidiol (CBD) shows promise as an anti-seizure and anti-inflammatory agent.

Purpose of the Study:

• To review the neuroinflammatory and antiseizure activities of CBD.
• To explore CBD's mechanisms of action in epilepsy.
• To discuss the implications for future epilepsy treatments.

Main Methods:

• Review of in vitro and in vivo experimental studies.
• Analysis of randomized placebo-controlled trials.
• Examination of CBD's effects on receptor modulation and neuroinflammation.

Main Results:

• CBD reduces seizure frequency in specific epilepsy syndromes (LGS, DS, TSC).
• CBD modulates endocannabinoid, adenosine, GPR55, and TRPV1 receptors.
• CBD exhibits immunomodulatory effects, reducing neuroinflammation and proinflammatory factors.

Conclusions:

• CBD's anti-inflammatory and antiseizure properties offer therapeutic potential.
• Understanding CBD's mechanisms can guide targeted treatment and biomarker development.
• Further studies may expand CBD's use to other epilepsy types.